Venclexta (Venetoclax)
venetoclax 100 mg tablet, 120 · ORAL · PBS code 12199C
AUTHORITY_REQUIREDWhat it costs
AU$7241.87 PBS-determined price per 120 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2020-12-01.
- • Repeats: 5.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
Second and final continuing treatment prescription (treatment cycles 7 to 12 inclusive) of first-line therapy
Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND
The treatment must cease upon disease progression; or
The treatment must cease upon completion of 12 cycles of treatment with this drug for this condition, whichever comes first; AND
The treatment must be in combination with obinutuzumab (refer to Product Information for timing of obinutuzumab and venetoclax doses); AND
The treatment must not be in combination with acalabrutinib.
Sponsor: AbbVie Pty Ltd ABN 48 156 384 262
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.